- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055600
Milk-only Lactation Study for Patients on Eltrombopag
May 11, 2015 updated by: GlaxoSmithKline
A Phase IV Study Evaluating Eltrombopag Concentrations in Breast Milk of Nursing Mothers Taking Eltrombopag
This is a Phase IV study to evaluate eltrombopag concentrations in breast milk of nursing mothers taking marketed eltrombopag (PROMACTA®).
Up to 10 subjects (mother-infant pairs) at as many as 10 study centers in the US will be enrolled.
Nursing mothers who are registered with the PROMACTA Pregnancy Registry will be offered the option to participate in this trial if they continue to take commercial eltrombopag post-delivery and decide to breastfeed their infant.
Information will be collected in a diary.
Breast milk samples will be collected before and after infant feedings for a 24 hour period after eltrombopag dosing to evaluate the eltrombopag concentrations in the breast milk.
Mothers will also be given the option to have a pharmacokinetic (PK) blood sample collected from the infant.
Study Overview
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Research Triangle Park, North Carolina, United States, 27709
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 weeks to 5 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mother is registered with the PROMACTA Pregnancy Registry and meets all the enrollment criteria defined in the PROMACTA Pregnancy Registry study (113327).
- Mother is continuing to take eltrombopag.
- Mother has received 7 consecutive eltrombopag doses prior to the milk sample collection.
- Infant is 4 weeks to 26 weeks of age at the time of milk sampling.
- Exclusively breastfeeding mother-infant pair; either via breast or with expressed milk from the mother.
- Mother is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria:
- Infant was born with complications that could impact ability to participate in this study.
- Breastfeeding is not well established in the mother-infant pair (e.g., poor latching of the infant or low milk supply).
- Infants who are supplemented with formula or are consuming solid foods.
- Unwillingness or inability of mother to follow the procedures outlined in the protocol.
- Mother is mentally or legally incapacitated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study
Mothers are taking PROMACTA prescribed by their physician before entering this study.
No drug will be administered as part of this study.
|
Mothers are taking PROMACTA prescribed by their physician before entering this study.
No drug will be administered as part of this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Breast milk eltrombopag concentrations collected from nursing mothers taking eltrombopag
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AEs in infant reported during the 24 hour breast milk collection period
Time Frame: 24 hours
|
24 hours
|
Plasma eltrombopag concentrations from infant, as data permit (optional)
Time Frame: 1 sample within 2 days
|
1 sample within 2 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
July 1, 2014
Study Completion (Anticipated)
July 1, 2014
Study Registration Dates
First Submitted
January 7, 2010
First Submitted That Met QC Criteria
January 21, 2010
First Posted (Estimate)
January 25, 2010
Study Record Updates
Last Update Posted (Estimate)
May 13, 2015
Last Update Submitted That Met QC Criteria
May 11, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 113101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopaenia
-
GlaxoSmithKlineCompletedThrombocytopaeniaSpain, Taiwan, Bulgaria, United States, Argentina, Russian Federation, Germany, Korea, Republic of, Austria, India, Italy, United Kingdom, Poland, Romania, Ukraine, Hungary, Peru, Czech Republic, Mexico
-
GlaxoSmithKlineCompletedThrombocytopaeniaUnited States, Germany, Israel, Belgium, Finland, Ireland, Italy, Greece, India, Czech Republic, Hungary, Canada, Poland
-
GlaxoSmithKlineCompletedThrombocytopaeniaUnited States
-
GlaxoSmithKlineCompletedThrombocytopaeniaUnited States
-
Novartis PharmaceuticalsCompletedThrombocytopaeniaBelgium, Greece, Netherlands, Romania, China, Korea, Republic of, Tunisia, France, Hong Kong, Ireland, Peru, Poland
-
Novartis PharmaceuticalsTerminatedThrombocytopaeniaUnited States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
-
Novartis PharmaceuticalsCompletedThrombocytopaeniaUnited States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
Clinical Trials on eltrombopag
-
Novartis PharmaceuticalsCompletedPurpura, Thrombocytopenic, IdiopathicRussian Federation
-
Fondazione Progetto EmatologiaCompletedChronic Lymphocytic Leukemia | Purpura, Thrombocytopenic, Idiopathic | Non Hodgkin's Lymphoma | Autoimmune Thrombocytopenia | Autoimmune Thrombocytopenic PurpuraItaly
-
Weill Medical College of Cornell UniversityNovartisTerminatedImmune ThrombocytopeniaUnited States
-
Institute of Hematology & Blood Diseases Hospital...Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaboratorsActive, not recruitingPreviously Treated Primary Immune ThrombocytopeniaChina
-
Tel-Aviv Sourasky Medical CenterNovartisRecruitingB Cell Lymphoma | CART TreatmentIsrael
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPrimacy Immune ThrombocytopeniaItaly
-
Novartis PharmaceuticalsCompletedPurpura, Thrombocytopaenic, Idiopathic
-
Nanfang Hospital of Southern Medical UniversityGuangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaboratorsUnknownAcute Myeloid Leukemia | Thrombocytopenia | EltrombopagChina
-
IRCCS Policlinico S. MatteoCompleted